Yes, drug and medical device mass tort cases are fundamentally reshaping civil litigation in 2026. As of March 2026, federal courts are managing 199,000 pending multidistrict litigation (MDL) cases with a combined potential settlement value exceeding $50 billion, making the pharmaceutical and medical device landscape one of the most active litigation sectors in the country. These cases span decades-old product liability claims, emerging drug side-effect litigation, and environmental contamination disputes—each one involving thousands of individual plaintiffs seeking compensation for injury or illness allegedly caused by defective medications or implanted devices. The scale of this litigation wave has become impossible to ignore. The Purdue Pharma settlement, which became effective in 2026 after years of negotiation, exemplifies how these mass tort cases shape not just individual recoveries but entire corporate structures and compensation frameworks.
Simultaneously, new litigation waves are emerging—GLP-1 weight-loss drugs like Ozempic and Mounjaro are generating thousands of injury claims, while PFAS (forever chemicals) contamination cases are targeting $12 billion or more in settlements across multiple jurisdictions. The combination of older cases reaching resolution and new ones entering the MDL system means that 2026 will be a pivotal year for determining how much money ultimately flows to plaintiffs and which companies bear the greatest financial burden. These cases involve some of the most widely used medications and medical devices in America. Patients who took these products were often unaware of their potential health risks, trusting that FDA approval or market availability meant safety. When complications arose—from gastrointestinal injuries to autoimmune reactions—many discovered they were part of a broader pattern of harm that warranted legal action. Understanding the current state of mass tort litigation helps patients, their families, and healthcare professionals recognize which products have active claims and what compensation may still be available.
Table of Contents
- How Many People Are Involved in Mass Tort Cases Right Now?
- What Makes 2026 Different From Previous Years of Mass Tort Litigation?
- Which Drug and Device Cases Are Dominating Litigation in 2026?
- How Do Mass Tort Settlements Actually Work?
- What Are the Major Obstacles Courts and Claimants Face?
- What New Litigation Waves Are Emerging Beyond the Major Cases?
- How Are Recent Court Rulings Shifting the Landscape?
How Many People Are Involved in Mass Tort Cases Right Now?
The 199,000 pending MDL cases represent a staggering number of individual plaintiffs—often 100 to 500 people per case, though some MDLs consolidate 10,000 or more claims under one judge’s authority. These numbers grew consistently throughout 2025 and into 2026 as new cases were filed and existing cases moved through discovery and settlement negotiations. The sheer volume creates significant pressure on federal court dockets, forcing judges to prioritize which cases proceed to trial and which are resolved through negotiated settlements. Courts have also implemented case management techniques like bellwether trials (representative cases tried first to help settle the remainder) to manage the workload. Different product categories account for different portions of this caseload.
Pharmaceutical cases historically dominate the numbers—everything from cancer medications with unexpected cardiovascular side effects to pain relievers linked to liver damage or stroke. Medical device cases are growing, particularly hernia mesh litigation with 26,153 pending cases as of early 2026, many of which involve complications like infection, recurrence, or chronic pain years after implantation. Environmental and chemical contamination cases, especially PFAS litigation, are one of the fastest-growing categories, with some analysts projecting these alone could eventually rival opioid litigation in total claims volume. The financial exposure is not evenly distributed. Large pharmaceutical companies with multiple products in litigation face billions of dollars in potential liability, while smaller device manufacturers or generic drug producers may see their financial survival threatened by a single major verdict or settlement. This asymmetry creates very different negotiating dynamics—some companies settle aggressively to limit exposure, while others litigate harder, betting that trial outcomes will be more favorable than settlement terms suggest.
What Makes 2026 Different From Previous Years of Mass Tort Litigation?
The critical difference in 2026 is the convergence of three trends: resolution of older cases, emergence of new pharmaceutical litigation waves, and increasing scrutiny of manufacturer conduct during the pre-litigation period. The Purdue Pharma settlement, which became effective in 2026, closed a major chapter in opioid litigation that had dominated mass tort conversations for more than a decade. While individual states, cities, and tribes will receive settlements stretching over many years, the initial implementation of the agreement signals that even the largest pharmaceutical mass torts eventually reach an endpoint. However, this resolution also freed up court and legal resources that are now being redirected to other cases. The emergence of GLP-1 litigation represents a qualitative shift in how quickly new drug side effects are being litigated.
These weight-loss and diabetes medications became blockbuster drugs in 2022 and 2023, and by 2026, thousands of injury claims had already been filed alleging gastrointestinal complications, thyroid issues, or off-label use complications. This is far faster than historical timelines—compare this to hernia mesh litigation, which took years to build momentum, or to some cancer drug cases that took a decade to generate significant lawsuit volume. Faster litigation means companies face financial uncertainty earlier in a product’s commercial life, potentially affecting pricing, insurance coverage, and clinical decision-making while the drug is still widely prescribed. One significant limitation of current mass tort litigation is that settlements, while substantial, often cannot compensate all injured individuals equally. Some plaintiffs may receive $50,000 while others with identical injuries receive $200,000 or more, depending on factors like severity documentation, jurisdiction, and how aggressively their attorneys negotiated. Additionally, not all injured individuals even know they have claims—some PFAS cases target companies whose product caused groundwater contamination in residential areas, but affected residents may be unaware of the link between the chemical and their health issues, meaning many eligible claimants never file.
Which Drug and Device Cases Are Dominating Litigation in 2026?
GLP-1 weight-loss drugs represent the most visible emerging litigation wave of 2026. Ozempic, Mounjaro, Zepbound, and competing products have generated thousands of claims alleging severe gastrointestinal complications, including stomach paralysis, dehydration, and intestinal obstruction. Many of these cases allege that the manufacturers downplayed the severity or frequency of these side effects in their marketing and medical literature, particularly when promoting off-label use for weight loss in non-diabetic patients. The cases are still in early stages, but bellwether trials are being scheduled for later in 2026, which will give both sides a clearer picture of potential jury verdicts and settlement values. Hernia mesh litigation continues to generate significant claims despite years of prior litigation. A recent ruling by a federal judge against Covidien (now part of Medtronic) regarding design defects in certain mesh products has emboldened additional plaintiffs to pursue claims they might have previously settled for less money.
The 26,153 pending cases involve complications ranging from mesh migration to chronic inflammatory responses requiring revision surgery. Because hernia repair is one of the most common surgical procedures in America, the total number of people affected is enormous—even a small percentage of the estimated 20 million Americans who undergo hernia repair in any given decade represents a substantial litigation pool. PFAS (per- and polyfluoroalkyl substances) litigation targeting $12 billion or more in settlements involves groundwater contamination, mostly from firefighting foam at military bases and airports, but also from industrial manufacturing. Companies like 3M, DuPont, and others face thousands of claims from residents, municipalities, and water districts alleging that PFAS exposure caused diseases including kidney cancer, testicular cancer, thyroid disease, and immune system dysfunction. The federal government has designated some PFAS chemicals as toxic substances, which strengthens the legal arguments for plaintiffs but also creates complexity around which entities are responsible for cleanup versus compensation. Some PFAS settlements have already been reached, but the litigation continues to expand to new jurisdictions and new defendants.
How Do Mass Tort Settlements Actually Work?
Mass tort settlements are negotiated agreements between attorneys representing plaintiffs, defendants, and insurers that establish a settlement fund and criteria for distributing money to eligible claimants. In the Purdue Pharma case, the settlement reached approximately $7.4 billion, which was then distributed to states, localities, tribes, and individuals according to a predetermined formula. Not every plaintiff received an equal payment—the settlement administrator evaluated individual claims based on factors like the diagnosis, medical expenses, and evidence of Purdue product use. Some individuals received six-figure payouts while others received less than $10,000, reflecting differences in injury severity and claim strength. The timeline from settlement agreement to individual claim resolution can span years, particularly in large MDLs. After a settlement is announced and approved by a court, a claims administrator is appointed to manage the process. Claimants must submit documentation—medical records, proof of product purchase or use, photographs of injuries—to support their claims.
The administrator reviews each submission, and claimants can appeal denials. Defendants continue making settlement fund payments over time, often through annual installments rather than a lump sum. This extended payout schedule affects claimants’ ability to plan financially, particularly those dealing with ongoing medical complications. One tradeoff in settling a mass tort case is certainty versus potential for higher recovery through trial. When an individual opts into a mass tort settlement, they typically give up the right to sue independently or pursue a jury verdict in their own case. In exchange, they receive a predetermined amount, avoiding the risk and cost of individual litigation. However, some claimants who reject the settlement and pursue individual trials win substantially more than the settlement would have provided—though others lose at trial and recover nothing. The decision to accept or reject a settlement offer is deeply personal and depends on individual circumstances, risk tolerance, and the strength of the underlying medical evidence.
What Are the Major Obstacles Courts and Claimants Face?
Federal judges managing mass torts face unprecedented docket pressures. With 199,000 pending MDL cases and ongoing discoveries, motions, settlement conferences, and trials, the judicial system is stretched thin. Some judges must make decisions about consolidating cases, allowing certain claimants to proceed to trial while others are pressured to settle, and determining fair compensation frameworks for diverse injuries across different jurisdictions. This judicial bottleneck means that even cases with clear liability may take years to reach resolution, leaving plaintiffs in financial limbo while their health conditions may be worsening. A significant limitation of the current system is that not all injured people qualify for compensation, even if they were harmed by a product. Some settled cases have eligibility windows or claim deadlines—after a certain date, new claims cannot be filed.
For conditions with long latency periods (like some cancers from asbestos or environmental contamination), individuals may not develop symptoms or receive a diagnosis until after the claims deadline has passed. Additionally, some settlement agreements include damages caps or per-claimant maximums, meaning that a person with catastrophic injury caused by a defective product may recover far less than their actual medical expenses and lost wages. healthcare providers and patients also face a timing problem: litigation moves slowly, but pharmaceutical and device manufacturers sometimes continue selling products under legal clouds or with unresolved allegations. Doctors are left making treatment decisions without final litigation outcomes that might confirm or refute the alleged dangers. For example, certain opioid pain medications remained widely prescribed even as litigation advanced—patients had to make informed decisions based on incomplete information about the products’ risks and manufacturer conduct. This gap between injury suspicion and legal resolution creates ongoing public health uncertainty.
What New Litigation Waves Are Emerging Beyond the Major Cases?
Hair relaxer cancer litigation represents one of the newest significant MDL formations in 2026. Plaintiffs are claiming that chemical relaxers used primarily by Black women cause uterine cancer and other gynecological malignancies. Several major defendants have already faced jury verdicts in bellwether trials, with some verdicts exceeding $100 million. The litigation is still in relatively early stages, with the federal MDL court scheduling bellwether trials for mid-2026 to test liability and damages theories.
This case category is significant because it involves a consumer product used by millions of American women, and epidemiological studies have shown elevated cancer risk among regular users. Acetaminophen-autism and acetaminophen-ADHD litigation, which had been dismissed in prior years, is being revived by an appeals court. New epidemiological evidence has suggested that prenatal or early-childhood acetaminophen exposure may be associated with neurodevelopmental disorders. This revival of acetaminophen claims is significant because the drug is so ubiquitous—it’s in over-the-counter pain relievers, cold medicines, and many prescription medications. If the litigation succeeds, it could generate claims from millions of parents whose children used the product and subsequently developed autism or ADHD.
How Are Recent Court Rulings Shifting the Landscape?
A recent federal judge’s ruling against Covidien (Medtronic) in hernia mesh litigation found that certain mesh designs had defects that could not be repaired after implantation, distinguishing these cases from earlier mesh litigation that was settled. This ruling has accelerated new cases and increased settlement demands in pending mesh litigation. The decision analyzed the product design history and found that the company had information about the defect risk but continued marketing the products, which strengthened plaintiffs’ design defect and failure-to-warn claims.
Such rulings become precedent that other judges reference, making subsequent similar cases stronger for plaintiffs. PFAS litigation has benefited from regulatory developments that define certain chemicals as hazardous substances, and from scientific studies showing health impacts at lower exposure levels than previously understood. Several municipal water systems have filed claims seeking billions in environmental remediation costs, while individual cancer patients have filed personal injury claims. A major water district settlement in one state against PFAS manufacturers for environmental contamination has established valuation models that are being used in other jurisdictions, creating more predictable settlement ranges and encouraging additional settlements rather than trials.